Nanomedicine Strategies to Target Tumor-Associated Macrophages

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 May 5

PMID 28471401

Citations 35

Authors

Karin Binnemars-Postma

Gert Storm

Jai Prakash

Affiliations

Soon will be listed here.

Abstract

In recent years, the influence of the tumor microenvironment (TME) on cancer progression has been better understood. Macrophages, one of the most important cell types in the TME, exist in different subtypes, each of which has a different function. While classically activated M1 macrophages are involved in inflammatory and malignant processes, activated M2 macrophages are more involved in the wound-healing processes occurring in tumors. Tumor-associated macrophages (TAM) display M2 macrophage characteristics and support tumor growth and metastasis by matrix remodeling, neo-angiogenesis, and suppressing local immunity. Due to their detrimental role in tumor growth and metastasis, selective targeting of TAM for the treatment of cancer may prove to be beneficial in the treatment of cancer. Due to the plastic nature of macrophages, their activities may be altered to inhibit tumor growth. In this review, we will discuss the therapeutic options for the modulation and targeting of TAM. Different therapeutic strategies to deplete, inhibit recruitment of, or re-educate TAM will be discussed. Current strategies for the targeting of TAM using nanomedicine are reviewed. Passive targeting using different nanoparticle systems is described. Since TAM display a number of upregulated surface proteins compared to non-TAM, specific targeting using targeting ligands coupled to nanoparticles is discussed in detail.

Citing Articles

Failed Induction of the T1 System in T2 Dominant Patients: The Cancer-Permissive Immune Macroenvironment.

Yanuck S Integr Med (Encinitas). 2024; 23(2):24-35.

PMID: 38911450 PMC: 11193407.

Prognostic and clinical significance of tumor-associated macrophages in esophageal squamous cell carcinoma after surgery: do biomarkers and distributions matter?.

Yi B, Zeng J, Li L, Zhang J, Chen Y, Gao Y Biosci Rep. 2024; 44(4).

PMID: 38501293 PMC: 10994813. DOI: 10.1042/BSR20231194.

Platelets as delivery vehicles for targeted enrichment of NO to cerebral glioma for magnetic resonance imaging.

Ding Y, Ge M, Zhang C, Yu J, Xia D, He J J Nanobiotechnology. 2023; 21(1):499.

PMID: 38129881 PMC: 10734142. DOI: 10.1186/s12951-023-02245-y.

Role of microRNA-494 in tumor progression.

Maharati A, Akhlaghipour I, Taghehchian N, Yazdi Z, Moghbeli M Am J Transl Res. 2023; 15(11):6342-6361.

PMID: 38074823 PMC: 10703645.

Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy.

Zhu J, Fan J, Xia Y, Wang H, Li Y, Feng Z Front Pharmacol. 2023; 14:1271321.

PMID: 37808190 PMC: 10551637. DOI: 10.3389/fphar.2023.1271321.

References

Rossi L, Serafini S, Antonelli A, Pierige F, Carnevali A, Battistelli V . Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target. 2005; 13(2):99-111. DOI: 10.1080/10611860500064123. View

Arnaout M . Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 1990; 75(5):1037-50. View

Zhang W, Zhu X, Sun H, Xiong Y, Zhuang P, Xu H . Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010; 16(13):3420-30. DOI: 10.1158/1078-0432.CCR-09-2904. View

Raes G, Brys L, Dahal B, Brandt J, Grooten J, Brombacher F . Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol. 2004; 77(3):321-7. DOI: 10.1189/jlb.0304212. View

White E, Strom S, Wys N, Arenberg D . Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol. 2001; 166(12):7549-55. DOI: 10.4049/jimmunol.166.12.7549. View

Edwards J, Emens L . The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. Int Immunopharmacol. 2010; 10(10):1220-8. PMC: 2949513. DOI: 10.1016/j.intimp.2010.07.002. View

Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S . Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010; 70(6):2235-44. DOI: 10.1158/0008-5472.CAN-09-2335. View

Fleisch H . Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res. 1989; 116:1-28. DOI: 10.1007/978-3-642-83668-8_1. View

Mantovani A, Allavena P, Sica A . Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004; 40(11):1660-7. DOI: 10.1016/j.ejca.2004.03.016. View

10.

Locati M, Mantovani A, Sica A . Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol. 2013; 120:163-84. DOI: 10.1016/B978-0-12-417028-5.00006-5. View

11.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

12.

Niu M, Naguib Y, Aldayel A, Shi Y, Hursting S, Hersh M . Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol Pharm. 2014; 11(12):4425-36. PMC: 4255729. DOI: 10.1021/mp500565q. View

13.

Lazennec G, Richmond A . Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010; 16(3):133-44. PMC: 2840699. DOI: 10.1016/j.molmed.2010.01.003. View

14.

Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View

15.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

16.

Agrawal A, Manchester M . Differential uptake of chemically modified cowpea mosaic virus nanoparticles in macrophage subpopulations present in inflammatory and tumor microenvironments. Biomacromolecules. 2012; 13(10):3320-6. PMC: 3590107. DOI: 10.1021/bm3010885. View

17.

Daldrup-Link H, Golovko D, Ruffell B, DeNardo D, Castaneda R, Ansari C . MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res. 2011; 17(17):5695-704. PMC: 3166957. DOI: 10.1158/1078-0432.CCR-10-3420. View

18.

Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

19.

Dumitru C, Lang S, Brandau S . Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013; 23(3):141-8. DOI: 10.1016/j.semcancer.2013.02.005. View

20.

Sica A, Schioppa T, Mantovani A, Allavena P . Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006; 42(6):717-27. DOI: 10.1016/j.ejca.2006.01.003. View